Upload Avatar (500 x 500)
Bin Xu
xubin_oncology@whu.edu.cn
English, Chinese
Hubei
Wuhan University
Medical School
  • 2004.09-2011.06: Master's Degree in Clinical Medicine from Wuhan University
  • 2013.09-2016.11: PhD in Internal Medicine from Wuhan University
  • Second Prize of Hubei Province Science and Technology Progress Award
  • 2011.07-2014.05: Resident Physician at Oncology Department, Renmin Hospital of Wuhan University
  • 2014.06-2020.11: Attending Physician at Oncology Department, Renmin Hospital of Wuhan University
  • 2020.12-present: Associate Chief Physician at Oncology Department, Renmin Hospital of Wuhan University
  • 2020: Second Prize of Hubei Province Science and Technology Progress Award for innovation and application of targeted and intelligent radiotherapy quality control system
  • 2022: Highly Downloaded Paper on the development and prospects of tumor immunotherapy drugs
  • 2014: Third Prize in the 2013 Annual Medical Education Excellent Papers by the Chinese Medical Association and the China Higher Education Society Medical Education Professional Committee
  • 2019: Second Prize for Excellent Paper at the Annual Meeting of the Hubei Provincial Medical Association Radiation Oncology Branch
Lung cancer research
Tumor immune microenvironment and precision therapy
  • Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer, Zuo Y, Zhong J, Bai H, Xu B et al., 2022
  • A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma, Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, Xu B, 2021
  • CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value, Wu J, Li L, Wu S, Xu B, 2020
  • Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma, Zhang H, Yao Y, Wu J, Zhou J, Zhao C, He J, Xu B, 2022
  • Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer, Zhu L, Ye D, Lei T, Wu J, Wang W, Xu B, 2022
  • Oncolytic Adenovirus: Prospects for Cancer Immunotherapy, Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H, Lei T, Xu B, 2021
  • Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study, Xu B, Song KH, Yao Y, et al., 2021
  • Prognostic nomogram for predicting survival in patients with high grade endometrial stromal sarcoma: a Surveillance Epidemiology, and End Results database analysis, Wu J, Zhang H, Li L, Hu M, Chen L, Wu S, Xu B, Song Q, 2020
  • Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis, Zhao Y, Wu J, Li L, Zhang H, Zhang H, Li J, Zhong H, Lei T, Jin Y, Xu B, Song Q, 2022
Lung Cancer Clinical Translation Tumor Immune Microenvironment Precision Therapy Research Oncology Treatment Diagnosis Cancer Therapy Clinical Innovation

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.